Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prevenar 20
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Prevenar 20 is a 20-valent pneumococcal conjugate vaccine developed by Pfizer to provide broad protection against invasive pneumococcal disease and pneumonia caused by *Streptococcus pneumoniae*. It contains capsular polysaccharides from 20 different serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F), each individually conjugated to the CRM197 carrier protein. This vaccine builds upon the earlier Prevnar 13 by adding seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) that are associated with high disease burden, antibiotic resistance, and severity. It is indicated for active immunization in individuals aged 6 weeks and older to prevent diseases such as meningitis, bacteremia, and pneumonia.
- Brand names
- Prevenar 20Prevenar20Prevenar-20Prevnar 20Prevnar20Prevnar-20Apexxnar
- Other names
- 20-valent pneumococcal conjugate vaccine20vPnCPneumococcal 20-valent conjugate vaccinePneumococcal20-valent conjugate vaccinePneumococcal-20-valent conjugate vaccine
02
Targets
PCV20 antigens (20-valent pneumococcal capsular polysaccharide antigens)
Beyond the preview
Go deeper on Prevenar 20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prevenar 20.